Description

Traken 100 mg (Tramadol Hydrochloride)

Traken 100 mg is an oral, centrally acting dual-mechanism analgesic formulation containing tramadol hydrochloride. It produces analgesia through two complementary pathways: low-affinity binding as an agonist at $\mu$-opioid receptor sites, and simultaneous inhibition of the neuronal reuptake of norepinephrine and serotonin ($\text{5-HT}$). This combined pharmacodynamic profile modifies both ascending nociceptive processing and descending inhibitory pain pathways within the central nervous system.

Product Overview

Primary Indications

Traken 100 mg is indicated under licensed clinical supervision for:

• Moderate to Moderately Severe Acute Pain: Short-term relief of severe acute musculoskeletal injuries, post-traumatic distress, or post-surgical pain where non-opioid regimens (e.g., standard NSAIDs or paracetamol) prove insufficient or clinically inappropriate.

• Refractory Chronic Pain: Controlled management of persistent, chronic pain conditions (such as severe degenerative joint disease or neuropathic pain syndromes) when alternative analgesic strategies fail to achieve adequate functional relief.

Key Information & Precautions

• Dosage & Daily Ceilings: Must be administered strictly in accordance with physician guidance. The total daily intake of immediate-release tramadol should generally not exceed 400 mg per day in adults with normal renal and hepatic function (often lower, e.g., 300 mg/day, in elderly patients or those with organ impairment) to minimize the risk of severe adverse events.

• CYP2D6 Polymorphism & Variable Analgesia: The analgesic efficacy of tramadol heavily depends on its bioactivation to the potent $\text{M1}$ metabolite by the cytochrome P450 2D6 (CYP2D6) enzyme. “Poor metabolizers” may experience inadequate pain relief, whereas “ultra-rapid metabolizers” face an elevated risk of rapid toxicity and respiratory depression even at standard therapeutic doses.

• Seizure Vulnerability: Tramadol significantly lowers the seizure threshold. Convulsion risks escalate sharply at elevated dosages or when co-administered with epileptogenic medications, including SSRIs, SNRIs, tricyclic antidepressants, bupropion, or antipsychotics.

• Serotonin Syndrome Hazard: Due to its monoaminergic reuptake inhibition, concurrent administration with other serotonergic agents (e.g., MAOIs, triptans, linezolid, St. John’s Wort) can precipitate life-threatening serotonin toxicity (hyperreflexia, autonomic instability, clonus, hyperthermia).

• Dependence, Tolerance, and Misuse Liability: Although possessing lower $\mu$-opioid receptor affinity than classic strong opioids, tramadol carries a confirmed liability for physical dependence, tolerance, and substance misuse.

• Atypical Withdrawal Profile: Sudden discontinuation after prolonged therapy can induce conventional opioid withdrawal symptoms (sweating, chills, nausea, tachycardia) alongside atypical neuropsychiatric effects tied to serotonin/norepinephrine rebound (panic, hallucinations, paresthesias). Tapering is mandatory.

• Boxed Warning — Concomitant Depressants & Respiratory Depression: Co-administration with benzodiazepines, other sedative-hypnotics, or alcohol dramatically amplifies the risk of profound sedation, life-threatening respiratory depression, coma, and fatal overdose.

• Impairment of Motor Skills: Tramadol frequently causes somnolence, dizziness, and cognitive dampening. Operating motor vehicles or complex machinery is strictly ill-advised until individual patient tolerance is fully confirmed.